EGFR and non-small cell lung carcinoma: Our systematic analysis indicated that patients with EGFR ex20ins NSCLC who received novel targeted agents in the later-line setting achieved a pooled ORR of 41.8% (95% CI: 35.3%–48.3%) and DCR of 85.6% (95% CI: 80.1%–91.1%).